Mario Petrini, Gianluca Gaidano, Andrea Mengarelli, Ugo Consoli, Armando Santoro, Anna Maria Liberati, Marco Ladetto, Vincenzo Fraticelli, Attilio Guarini, Donato Mannina, Paola Ferrando, Paolo Corradini, Pellegrino Musto, Caterina Stelitano, Dario Marino, Andrea Camera, Marco Murineddu, Roberta Battistini, Giuseppe Caparrotti, Mauro Turrini, Luca Arcaini, Simone Santini, Manuela Cerqueti, Andres J M Ferreri, Nicola Cantore, Alessandro Inzoli, Giovanni Cardinale, Benedetto Ronci, Giorgio La Nasa, Stefano Massimi, Gianfranco Gaglione, Valentina Barbiero, Maurizio Martelli
Subcutaneous (SC) rituximab may be beneficial in terms of convenience and tolerability, with potentially fewer and less severe administration-related reactions (ARRs) compared to the intravenous (IV) form. This report presents the results of a phase IIIb study conducted in Italy. The study included adult patients with CD20+ DLBCL or FL having received at least one full dose of IV RTX 375 mg/m2 during induction or maintenance. Patients on induction received ≥4 cycles of RTX SC 1400 mg plus standard chemotherapy and FL patients on maintenance received ≥6 cycles of RTX SC...
2022: Advances in Hematology